Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Si Chen & Chen Yan. (2021) An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases. Expert Opinion on Drug Discovery 16:2, pages 183-196.
Read now
Read now
Josef Stehlik & Matthew A Movsesian. (2006) Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert Opinion on Investigational Drugs 15:7, pages 733-742.
Read now
Read now
Articles from other publishers (56)
Sumon Roy, Robert A. Kloner, Fadi N. Salloum & Ion S. Jovin. (2021) Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. Cardiovascular Drugs and Therapy 37:4, pages 793-806.
Crossref
Crossref
Rima Kamel, Jérôme Leroy, Grégoire Vandecasteele & Rodolphe Fischmeister. (2022) Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure. Nature Reviews Cardiology 20:2, pages 90-108.
Crossref
Crossref
Nada Banjac, Velibor Vasović, Nebojša Stilinović, Ana Tomas, Lucija Vasović, Nikola Martić, Dušan Prodanović & Vladimir Jakovljević. (2023) The Effects of Different Doses of Sildenafil on Coronary Blood Flow and Oxidative Stress in Isolated Rat Hearts. Pharmaceuticals 16:1, pages 118.
Crossref
Crossref
M. Goweder Fawzia, T. M. Abu El-Nasr & A. A. El-Sayed. (2021) The effect of sesame intake on adult albino rat testis during sildenafil long-term administration. The Journal of Basic and Applied Zoology 82:1.
Crossref
Crossref
Adinoyi Seriki Samuel. (2021) Sildenafil citrate in healthy and diseased hearts. Journal of Cardiology and Cardiovascular Medicine 6:1, pages 033-039.
Crossref
Crossref
Yoshiko Okai, Keiko Matsune, Kazunori Yamanaka, Toshikatsu Matsui, Emily Pfeiffer Kaushik, Kosuke Harada, Hiroshi Kohara, Akimitsu Miyawaki, Harushige Ozaki, Matthew Wagoner & Tadahiro Shinozawa. (2020) Video-based assessment of drug-induced effects on contractile motion properties using human induced pluripotent stem cell-derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods 105, pages 106893.
Crossref
Crossref
Michael E. J. Preedy. (2020) Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure. Cardiovascular Drugs and Therapy 34:3, pages 401-417.
Crossref
Crossref
Edwin A. Li, Wang Xi, Young Soo Han & Frank V. Brozovich. (2019) Phosphodiesterase expression in the normal and failing heart. Archives of Biochemistry and Biophysics 662, pages 160-168.
Crossref
Crossref
Anastacia M. GarciaStephanie J. NakanoAnis Karimpour-FardKarin NunleyPenny Blain-NelsonNatalie M. StaffordBrian L. StaufferCarmen C. SucharovShelley D. Miyamoto. (2018) Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro. Circulation: Heart Failure 11:9.
Crossref
Crossref
Kun Liu, Qiongyu Hao, Jie Wei, Gong-Hao Li, Yong Wu & Yun-Feng Zhao. (2018) MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A. Journal of Hypertension 36:9, pages 1847-1857.
Crossref
Crossref
Hiroshi Watanabe & Quang-Kim Tran. 2017. Diagnosis and Treatment of Pulmonary Hypertension. Diagnosis and Treatment of Pulmonary Hypertension
139
151
.
R. Pofi, D. Gianfrilli, R. Badagliacca, C. Di Dato, M. A. Venneri & E. Giannetta. (2015) Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. Journal of Endocrinological Investigation 39:2, pages 131-142.
Crossref
Crossref
Chantal V. Degen, Kalkidan Bishu, Rosita Zakeri, Ozgur Ogut, Margaret M. Redfield & Frank V. Brozovich. (2015) The Emperor's New Clothes: PDE5 and the Heart. PLOS ONE 10:3, pages e0118664.
Crossref
Crossref
V.O. Oka, A.L. Udefa, V.U. Nna & D.U. Owu. (2015) Sildenafil Citrate and Tramadol Administered Separately and in Combination Affects Basal Metabolic Rate, Triiodothyronine (T3) and Cortisol Levels in Albino Wistar Rats. Trends in Medical Research 10:3, pages 51-62.
Crossref
Crossref
Walter Knight & Chen Yan. (2013) Therapeutic potential of PDE modulation in treating heart disease. Future Medicinal Chemistry 5:14, pages 1607-1620.
Crossref
Crossref
Nilanjana Ph. D.Mahesh Thirunavukkarasu & Murugavel Ponnusamy. 2013. Cardiovascular Diseases. Cardiovascular Diseases
439
458
.
David A. Kass. (2012) Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials. Current Heart Failure Reports 9:3, pages 192-199.
Crossref
Crossref
Dong I. Lee & David A. Kass. (2012) Phosphodiesterases and Cyclic GMP Regulation in Heart Muscle. Physiology 27:4, pages 248-258.
Crossref
Crossref
B. Preckel, S. Eberl, J. Fr??dorf & M.W. Hollmann. (2012) Management von Patienten mit pulmonaler HypertonieManagement of patients with pulmonary hypertension. Der Anaesthesist 61:7, pages 574-587.
Crossref
Crossref
B. A. Carabello. (2012) Georg Ohm and the Changing Character of Aortic Stenosis: It's Not Your Grandfather's Oldsmobile. Circulation 125:19, pages 2295-2297.
Crossref
Crossref
A.R. Harmer, N. Abi-Gerges, M.J. Morton, G.F. Pullen, J.P. Valentin & C.E. Pollard. (2012) Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicology and Applied Pharmacology 260:2, pages 162-172.
Crossref
Crossref
Clarke E. Atkins & Jens Häggström. (2012) Pharmacologic management of myxomatous mitral valve disease in dogs. Journal of Veterinary Cardiology 14:1, pages 165-184.
Crossref
Crossref
B. R. Lindman & M. M. Chakinala. (2010) Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension. International Journal of Clinical Practice 64, pages 15-22.
Crossref
Crossref
Clint L. Miller & Chen Yan. (2010) Targeting Cyclic Nucleotide Phosphodiesterase in the Heart: Therapeutic Implications. Journal of Cardiovascular Translational Research 3:5, pages 507-515.
Crossref
Crossref
Sharron H. Francis, Jennifer L. Busch & Jackie D. Corbin. (2010) cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action. Pharmacological Reviews 62:3, pages 525-563.
Crossref
Crossref
Bo Jin, Xin-Ping Luo, Huan-Chun Ni & Hai-Ming Shi. (2010) Phosphodiesterase Type 5 Inhibitors for High-Altitude Pulmonary Hypertension. Clinical Drug Investigation 30:4, pages 259-265.
Crossref
Crossref
Tilman Humpl & Ingram Schulze-Neick. 2010. Paediatric Cardiology. Paediatric Cardiology
1147
1161
.
Judy W. M. Cheng & Selamawit R. Berhane. (2009) Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. American Journal of Lifestyle Medicine 3:3, pages 201-211.
Crossref
Crossref
Praneet Kumar, Gary S. Francis & W. H. Wilson Tang. (2009) Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nature Reviews Cardiology 6:5, pages 349-355.
Crossref
Crossref
Yuan James Rao & Lei Xi. (2008) Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacologica Sinica 30:1, pages 1-24.
Crossref
Crossref
S. Hsu, T. Nagayama, N. Koitabashi, M. Zhang, L. Zhou, D. Bedja, K. L. Gabrielson, J. D. Molkentin, D. A. Kass & E. Takimoto. (2008) Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovascular Research 81:2, pages 301-309.
Crossref
Crossref
Manling Zhang, Norimichi Koitabashi, Takahiro Nagayama, Ryan Rambaran, Ning Feng, Eiki Takimoto, Trisha Koenke, Brian O'Rourke, Hunter C. Champion, Michael T. Crow & David A. Kass. (2008) Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cellular Signalling 20:12, pages 2231-2236.
Crossref
Crossref
Marco Guazzi. (2008) Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure. Circulation: Heart Failure 1:4, pages 272-280.
Crossref
Crossref
David A. KassHunter C. ChampionJoseph A. Beavo. (2007) Phosphodiesterase Type 5. Circulation Research 101:11, pages 1084-1095.
Crossref
Crossref
D. A. Kass. (2007) Hypertrophied Right Hearts Get Two for the Price of One: Can Inhibiting Phosphodiesterase Type 5 Also Inhibit Phosphodiesterase Type 3?. Circulation 116:3, pages 233-235.
Crossref
Crossref
J. Nagendran, S. L. Archer, D. Soliman, V. Gurtu, R. Moudgil, A. Haromy, C. St. Aubin, L. Webster, I. M. Rebeyka, D. B. Ross, P. E. Light, J. R.B. Dyck & E. D. Michelakis. (2007) Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility. Circulation 116:3, pages 238-248.
Crossref
Crossref
J Y Jeremy, R A Jones, A J Koupparis, M Hotston, R Persad, G D Angelini & N Shukla. (2006) Reactive oxygen species and erectile dysfunction: possible role of NADPH oxidase. International Journal of Impotence Research 19:3, pages 265-280.
Crossref
Crossref
Oleg E. Osadchii. (2007) Myocardial Phosphodiesterases and Regulation of Cardiac Contractility in Health and Cardiac Disease. Cardiovascular Drugs and Therapy 21:3, pages 171-194.
Crossref
Crossref
E R Schwarz, V Kapur, J Rodriguez, S Rastogi & S Rosanio. (2006) The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. International Journal of Impotence Research 19:2, pages 139-148.
Crossref
Crossref
Pierre Fesler, Alberto Pagnamenta, Benoit Rondelet, François Kerbaul & Robert Naeije. (2006) Effects of sildenafil on hypoxic pulmonary vascular function in dogs. Journal of Applied Physiology 101:4, pages 1085-1090.
Crossref
Crossref
Shahzad G. Raja, Mark D. Danton, Kenneth J. MacArthur & James C. Pollock. (2006) Treatment of Pulmonary Arterial Hypertension With Sildenafil: From Pathophysiology to Clinical Evidence. Journal of Cardiothoracic and Vascular Anesthesia 20:5, pages 722-735.
Crossref
Crossref
Graham Jackson, Piero Montorsi & Melvin D. Cheitlin. (2006) Cardiovascular safety of sildenafil citrate (Viagra?): An updated perspective. Urology 68:3, pages 47-60.
Crossref
Crossref
Milan D. Patel & Stuart D. Katz. (2005) Phosphodiesterase 5 Inhibition in Chronic Heart Failure and Pulmonary Hypertension. The American Journal of Cardiology 96:12, pages 47-51.
Crossref
Crossref
Barry A. BorlaugVojtech MelenovskyTricia MarhinPatricia FitzgeraldDavid A. Kass. (2005) Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans. Circulation 112:17, pages 2642-2649.
Crossref
Crossref
K. Shinlapawittayatorn, S. Chattipakorn & N. Chattipakorn. (2005) Effect of sildenafil citrate on the cardiovascular system. Brazilian Journal of Medical and Biological Research 38:9, pages 1303-1311.
Crossref
Crossref
Jackie D. Corbin, Alfreda Beasley, Mitsi A. Blount & Sharron H. Francis. (2005) High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochemical and Biophysical Research Communications 334:3, pages 930-938.
Crossref
Crossref
Nilima Shukla, Robert Jones, Raj Persad, Gianni D. Angelini & Jamie Y. Jeremy. (2005) Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. European Journal of Pharmacology 517:3, pages 224-231.
Crossref
Crossref
G. Jackson, H. Gillies & I. Osterloh. (2005) Past, present, and future: a 7-year update of Viagra® (sildenafil citrate). International Journal of Clinical Practice 59:6, pages 680-691.
Crossref
Crossref
Eiki Takimoto, Hunter C Champion, Manxiang Li, Diego Belardi, Shuxun Ren, E Rene Rodriguez, Djahida Bedja, Kathleen L Gabrielson, Yibin Wang & David A Kass. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Medicine 11:2, pages 214-222.
Crossref
Crossref
E. Takimoto. (2004) cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism. Circulation Research 96:1, pages 100-109.
Crossref
Crossref
Gregory D. Lewis & Marc J. Semigran. (2004) Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Current Heart Failure Reports 1:4, pages 183-189.
Crossref
Crossref
Shahzad G. Raja & Suneela H. Nayak. (2004) Sildenafil: Emerging Cardiovascular Indications. The Annals of Thoracic Surgery 78:4, pages 1496-1506.
Crossref
Crossref
Michele M. Castro, Elen Rizzi, Ricardo R. Rascado, Sabrina Nagassaki, Lusiane M. Bendhack & Jose E. Tanus-Santos. (2004) Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. European Journal of Pharmacology 498:1-3, pages 189-194.
Crossref
Crossref
Shadwan F. Alsafwah & Stuart D. Katz. 2004. Sildenafil. Sildenafil
129
142
.
Jackie D. Corbin, Stephen R. Rannels & Sharron H. Francis. 2004. Heart Disease and Erectile Dysfunction. Heart Disease and Erectile Dysfunction
117
130
.
Sharron H. Francis & Jackie D. Corbin. (2003) Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Current Urology Reports 4:6, pages 457-465.
Crossref
Crossref